CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 61 enrolled
Drug / intervention
Ketorolacdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01832311
NCT01832311Phase 4Completed
CompareCT.gov

Protein Profile of Immunoregulatory Factors in Diabetic Cataract

University of Zagreb·interventional·Posted Apr 16, 2013·Updated Apr 16, 2013

In Brief

A Phase 4 clinical trial evaluating Ketorolac for Cataract and Type 2 Diabetes Mellitus. Completed, enrolled 61 participants across 2 sites.

Detailed Summary

The purpose of this study is to compare the levels of several immunoregulatory factors in serums and aqueous humor of type II diabetes cataract patients with those in senile non-diabetic cataract patients since disturbed cytokine and growth factor microenvironment in diabetic eye may contribute to an increased frequency of intraoperative and postoperative intraocular lens surgery complications.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract, Type 2 Diabetes Mellitus
CountriesCroatia
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 16, 2013
Enrollment StartJan 1, 2009
Primary CompletionDec 1, 2011
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 13.2 years ago

Interventions

Ketorolacdrug

Patients (both non-diabetic and diabetic) were randomized into subgroups receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac 0.5%, dosed 4 times a day, starting 3-7 days before surgery and ending 4-5 weeks after surgery respectively, and into subgroups not receiving NSAID.